<DOC>
	<DOCNO>NCT00338000</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness , safety clinical outcome Epoetin alfa dose regime accordance Summary Product Characteristics treatment anemia predialysis .</brief_summary>
	<brief_title>EPO-BUL-01 - Study Optimization Anemia Management EPREX ( Epoetin Alfa ) Predialysis Patients With Chronic Renal Failure</brief_title>
	<detailed_description>Open-label , non-randomized , multicenter study anemic patient hemoglobin &lt; or=11 g/dl . The dose epoetin alfa routine dosage regimen accordance approve SmPC . That 's study general two phase - first period : subcutaneous administration second period : intravenous administration . The evaluation make 4 visit : baseline , 2 month ( Visit 1 ) , 4 month ( Visit 2 ) , 6 month ( Visit 3 ) , 9 month ( Visit 4 ) . Echographic evaluation - baseline visit , Visit 3 Visit 4.Baseline visit - weight , arterial pressure , Hemoglobin , Hematocrit , Erythrocytes , Middle Cells Volume , Middle Cells Hemoglobin , Middle Cells Hemoglobin Concentration , Transferrin , Creatinine , Clerans , Visit1 , Visit 2 , Visit 3 , Visit 4 - Hemoglobin , Hematocrit , Erythrocytes , Middle Cells Volume , Middle Cells Hemoglobin , Middle Cells Hemoglobin Concentration . The dosage routine dose regimen , start dose epoetin alfa 50 Units/kg body weight . The maintain dose depends hematological result . Administration - subcutaneous ( first period ) , intravenous ( second period ) . Duration study - 9 month .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients Hb &lt; or= 11g/dl Females use adequate contraceptive method Patients uncontrolled severe cardiovascular disease , include recent myocardial infarction , uncontrolled hypertension congestive heart failure treatment within previous 6 month epoetin alfa erythropoietin , know hypersensitivity product ingredient patient line approve SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Chronic renal failure</keyword>
	<keyword>leave ventricular hypertrophy</keyword>
	<keyword>epoetin alfa</keyword>
</DOC>